Silvia Pierangeli, PhD
Professor, Division of Rheumatology
Silvia Pierangeli, PhD
Division of Rheumatology
Department of Internal Medicine
University of Texas Medical Branch
301 University Blvd.
Galveston, TX 77555-1165
Dr. Silvia S. Pierangeli is Professor of Medicine, Microbiology and Pathology and Director of the Antiphospholipid Standardization Laboratory at UTMB. Dr. Pierangeli received her B.S. and Ph.D. in Biochemistry degree from the Universidad de Buenos Aires in Argentina and subsequently a M.S. and a Ph.D. in Microbiology and Immunology from the University of Louisville, KY. She directs a research laboratory and a clinical laboratory at UTMB and she is certified by the College of American Pathologist to direct the antiphospholipid standardization laboratory, a reference center for testing on antiphospholipid antibodies at UTMB.
Her research interests are on Antiphospholipid Syndrome (APS) and lupus. Her laboratory is well-funded and is working on the pathogenic mechanisms to explain thrombosis in APS. These include intracellular mechanisms triggered by antiphospholipid antibodies on target cells and the receptor recognized for these antibodies on endothelial cells and platelets. Her laboratory is also interested in developing new targeted therapies to ameliorate and/or prevent clinical manifestations of APS. Dr. Pierangeli is funded with 2 NIH R0-1 grants and one grant from the US-Israeli Bi National Science Foundation and a grant from the Arthritis Research Campaign (UK).
Dr. Pierangeli was the chair and hosted the 13thIntenational Congress on Antiphospholipid Antibodies in Galveston, April 2010. She has been appointed as a member of the ACTS study section at NIAMS-NIH and is member of the editorial board of Lupus. Dr. Pierangeli is currently editing a book on Antiphospholipid Syndrome.
She has published more than 140 scientific papers in the field of APS. She has also contributed to numerous chapters in books and invited to present lectures and conferences in many congresses and symposia around the world and is reviewer for many scientific journals.
The department of internal medicine is developing evidence based clinical protocols which will be available in EPIC (as order sets) for use when admitting patients with these diagnoses. Their AIM is to standardize care and decrease length of stay and readmission rates.Currently available protocols are:
- CAP - Community Acquired Pneumonia Orderset
- Congestive Heart Failure (CHF)
- Chronic Obstructive Pulmonary Disease (COPD)
- Diabetic Ketoacidosis Adult, ICU
- General Medicine Admission
- Immunodeficiency Flow Panel
- MICU/CCU Admission Order Set
- Oral Analgesic Medicaitons
- Parenteral Opioids
- Sepsis, Adult ICU
- 111 - Stroke Alert
- 112 - Stroke Activation
- 300086 - Stroke Floor Admission
- 3000000001 - Stroke Critical care without tPA
- 300088 Stroke - Transfer from Critical care to floor
- 3004002 - Stroke Discharge
All protocols can be found in the EPIC order set section.
The department of Internal Medicine has a large role in the Meaningful Use Initiative. Our participation is key for the success of the initiative. Please visit the meaningful use website for important communication and updates from the Meaningful Use Initiative.